Clik here to view.
Masimo声学呼吸速率(RRa®)与Nellcor体积描记呼吸速率在志愿者中的性能比较研究
东京 (美国商业资讯) — Masimo (NASDAQ: MASI)今天宣布，日本东京女子医科大学麻醉科的研究人员发表了一项探寻志愿者呼吸速率测量方法的研究。方法是比较Masimo Radical-7®脉搏碳氧氧饱和度仪®测量的Masimo声学呼吸速率(Masimo)与Nellcor PM1000N测量的Nellcor体积描记呼吸速率(Nellcor) 1。 Smart News...
View ArticleClik here to view.
Saphetor and Supratech Leverage Genome Scale Analyses to Facilitate Precision...
LAUSANNE, Switzerland Saphetor SA, the Swiss precision-medicine company dedicated to advancing personalized diagnostics, announced today that it will provide its proprietary platform for analyzing...
View ArticleClik here to view.
加拿大卫生署NNHPD核准Graminex L.L.C.的PollenAid®和Prostanex®
密歇根州萨吉诺 (美国商业资讯)– 加拿大卫生署天然及非处方健康产品局(NNHPD)核准了Graminex® Flower Pollen Extracts™的生产商Graminex® LLC的PollenAid®和Prostanex® Flower Pollen Extract™制剂。...
View ArticleClik here to view.
グラミネックスがポレンエイドおよびプロスタネックスに対するカナダ保健省NNHPD承認を取得
米ミシガン州サギノー （ビジネスワイヤ）– グラミネックス花粉エキスを生産するグラミネックス（Graminex® LLC）は、ポレンエイド（PollenAid®）およびプロスタネックス（Prostanex®）の花粉エキス調製品に対し、カナダ保健省「天然・非処方健康食品局」（NNHPD）の承認を取得したと発表しました。...
View ArticleClik here to view.
Takeda and Molecular Templates Announce Multi-Target Research and Licensing...
OSAKA, Japan & AUSTIN, Texas Takeda Pharmaceutical Company Limited (TSE: 4502) and Molecular Templates, Inc. today announced a collaboration agreement for oncology drug discovery programs. The...
View ArticleClik here to view.
EP Vantage: Biopharma Stages a Strong Recovery over the First Half Even as...
LONDON & BOSTON & SAN FRANCISCO & TOKYO Today EP Vantage, the independent news and analysis arm of Evaluate Ltd, releases its 2017 half-year reports on pharma & biotech and medtech...
View ArticleClik here to view.
Swift Biosciences Announces New Industry-Leading Indexed Adapters for...
ANN ARBOR, Mich. Swift Biosciences, a leading provider of innovative library prep solutions for genomic sequencing, today announced the launch of Accel-NGS® 2S Indexed Adapters, a new portfolio of...
View ArticleClik here to view.
Swift Biosciences发布业界领先的新款标引接头，单次运行可测序的样本更多
密歇根州安娜堡 (美国商业资讯) — Swift Biosciences是面向基因组测序的创新文库制备解决方案的领先提供商，该公司今天宣布上市Accel-NGS®...
View ArticleClik here to view.
スウィフト・バイオサイエンシズ、1回のランで多数のサンプルをシーケンスできる業界最高レベルの新しいインデックス付きアダプターを発表
米ミシガン州アナーバー （ビジネスワイヤ）–ゲノムシーケンス用の革新的なライブラリー調製ソリューションを提供する一流のスウィフト・バイオサイエンシズは本日、Accel-NGS® 2Sインデックス付きアダプターの市場投入を発表しました。Accel-NGS®...
View ArticleClik here to view.
Starpharma: Successful VivaGel® Phase 3 Results and NDA Planned for rBV
MELBOURNE, Australia Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary...
View ArticleClik here to view.
Osprey Medical Announces Successful Over-subscribed Placement and Fully...
MINNESOTA, United States & MELBOURNE, Australia Osprey Medical Inc. (ASX:OSP) (Osprey or Company) today announces that it has received commitments from sophisticated and professional investors...
View ArticleClik here to view.
研究评估Masimo SpHb®在低血红蛋白水平创伤患者中的功效
瑞士纳沙泰尔 (美国商业资讯) — Masimo (NASDAQ: MASI)今天发布了一项新近发表研究的结果，该研究中，埃及开罗大学的研究人员评估了Masimo SpHb®（一种无创连续测量血红蛋白的方法）在低血红蛋白水平创伤患者中的功效1。...
View ArticleClik here to view.
低ヘモグロビン値の外傷患者における研究でMasimo SpHb®の性能を評価
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、カイロ大学（エジプト）の研究者らが最近公表した研究の結果を発表しました。研究は、低ヘモグロビン値の外傷患者でマシモの非侵襲的・連続的ヘモグロビン測定技術SpHb®の性能を評価したものです1。 Dr. Gamalと同僚らがこの前向き観察研究で低ヘモグロビン値（8...
View ArticleTaro Provides Results for Quarter Ended June 2017
HAWTHORNE, N.Y. Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2017. Quarter ended June 30, 2017...
View ArticleClik here to view.
Avita Medical to Present at Wedbush PacGrow Healthcare Conference
VALENCIA, Calif. & PERTH, Australia & LONDON Avita Medical, Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company developing innovative therapeutic solutions derived from the...
View ArticleClik here to view.
GI Dynamics to Provide Shareholder Update on 2017 Second Quarter Results
BOSTON & SYDNEY GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and...
View ArticleClik here to view.
GEN1 Biotechnology Raises AUD$8m (USD$6.3m)
ADELAIDE, Australia GEN1 Biotechnology Pty Ltd, a biopharmaceutical manufacturer based in Adelaide, Australia, has completed an AUD$8m (USD$6.3m) funding round, with an expected closing during...
View ArticleClik here to view.
FDA同意WIN联合会启动3种靶向药物用于转移性非小细胞肺癌一线治疗的临床试验
法国维勒瑞夫 (美国商业资讯) — 美国食品药品管理局(FDA)已核准WIN联合会(WIN)启动一种新型治疗方法的临床研究，该方法采用3种靶向药物联合，用于晚期非小细胞肺癌(NSCLC)患者的一线治疗。该研究名称为“理性创新基因组学延长生存期” (Survival Prolongation by Rationale Innovative Genomics,...
View ArticleClik here to view.
WINコンソーシアムが転移性非小細胞肺がんのファーストライン治療での分子標的薬3剤併用療法の臨床試験開始の承認をFDAより取得
仏ビルジュイフ （ビジネスワイヤ） — WINコンソーシアム（WIN）は、米食品医薬品局（FDA）より、進行性非小細胞肺がん（NSCLC） 患者のファーストライン治療で3種類の分子標的治療薬の組み合わせを使用した新規治療アプローチに対し、臨床試験開始の承認を受けました。SPRING（Survival Prolongation by Rationale Innovative...
View ArticleClik here to view.
Takeda and Shattuck Labs Announce Research Collaboration to Explore Agonist...
CAMBRIDGE, Mass. & AUSTIN, Texas Takeda Pharmaceutical Company Limited (TSE: 4502) and Shattuck Labs, Inc. announced today that they have entered into a research collaboration to explore and...
View Article